• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重复植入波士顿1型人工角膜的结果。

Outcomes of Repeat Boston Type 1 Keratoprosthesis Implantation.

作者信息

Ahmad Sumayya, Mathews Priya M, Srikumaran Divya, Aldave Anthony J, Lenis Tamara, Aquavella James V, Hannush Sadeer B, Belin Michael, Akpek Esen Karamursel

机构信息

Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland.

The Stein Eye Institute, Los Angeles, California.

出版信息

Am J Ophthalmol. 2016 Jan;161:181-7.e1. doi: 10.1016/j.ajo.2015.10.012. Epub 2015 Oct 23.

DOI:10.1016/j.ajo.2015.10.012
PMID:26482467
Abstract

PURPOSE

To describe the outcomes and prognostic characteristics of patients who had a repeat Boston type 1 keratoprosthesis (KPro) implantation.

DESIGN

Retrospective case series.

METHODS

setting: Data regarding preoperative clinical and demographic characteristics and postoperative course during initial and repeat KPro placement were collected at multiple centers across the country.

PATIENTS

Forty-eight eyes underwent explantation of KPro owing to complications between September 2003 and August 2014 at 5 participating tertiary eye care centers in the United States. Of those, 36 eyes that received a subsequent replacement device were included.

MAIN OUTCOME MEASURES

Visual acuity (VA) outcomes and postoperative complications.

RESULTS

Ocular surface disease was significantly more common in eyes that required a device explantation, compared to those that retained the device (P < .001). Sixty-seven percent of eyes (24/36) achieved VA ≥ 20/200 vision after the repeat KPro. The probability of these 24 eyes maintaining VA ≥ 20/200 after the repeat KPro was 87% at 1 year and 75% at 2 years. Predictors of the ability to maintain vision ≥ 20/200 following surgery were a better last-recorded vision before explantation (P = .0002) and better vision immediately after repeat KPro (P < .001).

CONCLUSION

Ocular surface disease and its complications were associated with more frequent device removal. In these patients, repeat KPro resulted in restoration of vision. A reasonable visual acuity prior to device removal was associated with favorable long-term postoperative visual acuity and retention.

摘要

目的

描述接受重复波士顿1型人工角膜(KPro)植入患者的治疗结果及预后特征。

设计

回顾性病例系列研究。

方法

背景:在全国多个中心收集了初次及重复植入KPro术前的临床和人口统计学特征以及术后病程的数据。

患者

2003年9月至2014年8月期间,在美国5家参与研究的三级眼科护理中心,48只眼因并发症接受了KPro取出术。其中,36只眼接受了后续的置换装置,纳入研究。

主要观察指标

视力(VA)结果及术后并发症。

结果

与保留装置的眼睛相比,需要取出装置的眼睛眼表疾病明显更常见(P <.001)。重复植入KPro后,67%的眼睛(24/36)视力达到≥20/200。这24只眼睛在重复植入KPro后1年保持视力≥20/200的概率为87%,2年时为75%。术后保持视力≥20/200的预测因素是取出装置前最后记录的视力较好(P =.0002)以及重复植入KPro后立即视力较好(P <.001)。

结论

眼表疾病及其并发症与更频繁的装置取出有关。在这些患者中,重复植入KPro可恢复视力。装置取出前合理的视力与良好的术后长期视力及装置保留有关。

相似文献

1
Outcomes of Repeat Boston Type 1 Keratoprosthesis Implantation.重复植入波士顿1型人工角膜的结果。
Am J Ophthalmol. 2016 Jan;161:181-7.e1. doi: 10.1016/j.ajo.2015.10.012. Epub 2015 Oct 23.
2
Predictors of visual outcomes following Boston type 1 keratoprosthesis implantation.波士顿1型人工角膜植入术后视觉预后的预测因素。
Am J Ophthalmol. 2015 Apr;159(4):739-47. doi: 10.1016/j.ajo.2014.12.024. Epub 2014 Dec 30.
3
Characteristics and management of patients with Boston type 1 keratoprosthesis explantation--the University of Montreal Hospital Center experience.波士顿1型人工角膜移植取出患者的特征与管理——蒙特利尔大学医院中心的经验
Am J Ophthalmol. 2014 Dec;158(6):1297-1304.e1. doi: 10.1016/j.ajo.2014.08.037. Epub 2014 Aug 28.
4
Long-term outcomes of boston type 1 keratoprosthesis implantation: a retrospective multicenter cohort.Boston 1 型角膜移植术的长期疗效:回顾性多中心队列研究。
Ophthalmology. 2014 Nov;121(11):2159-64. doi: 10.1016/j.ophtha.2014.05.030. Epub 2014 Jul 11.
5
Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis.加州大学戴维斯分校波士顿 1 型角膜假体的长期视力结果和并发症。
Ophthalmology. 2011 Aug;118(8):1543-50. doi: 10.1016/j.ophtha.2010.12.032. Epub 2011 Mar 12.
6
Boston type 1 keratoprosthesis: the CHUM experience.波士顿 1 型角膜假体:CHUM 经验。
Can J Ophthalmol. 2011 Apr;46(2):164-8. doi: 10.3129/i10-103.
7
Boston Type 1 Keratoprosthesis: Visual Outcomes, Device Retention, and Complications.波士顿1型人工角膜:视觉效果、装置保留情况及并发症
Cornea. 2016 Sep;35(9):1165-74. doi: 10.1097/ICO.0000000000000886.
8
Visual Outcomes and Complications of Type I Boston Keratoprosthesis in Children: A Retrospective Multicenter Study and Literature Review.儿童 I 型 Boston 角膜假体的视觉结果和并发症:回顾性多中心研究和文献复习。
Ophthalmology. 2018 Feb;125(2):153-160. doi: 10.1016/j.ophtha.2017.07.009. Epub 2017 Aug 12.
9
Gamma-irradiated corneas as carriers for the Boston type 1 keratoprosthesis: advantages and outcomes in a surgical mission setting.伽马射线辐照角膜作为波士顿 1 型角膜移植术的载体:手术任务环境下的优势和结果。
Cornea. 2014 Mar;33(3):235-9. doi: 10.1097/ICO.0000000000000065.
10
Donor Corneal Transplantation vs Boston Type 1 Keratoprosthesis in Patients with Previous Graft Failures: A Retrospective Single Center Study (An American Ophthalmological Society Thesis).既往移植失败患者的供体角膜移植术与波士顿1型人工角膜移植术对比:一项回顾性单中心研究(美国眼科学会论文)
Trans Am Ophthalmol Soc. 2015;113:T3.

引用本文的文献

1
Twelve-Month Clinical and Histopathological Performance of a Novel Synthetic Cornea Device in Rabbit Model.新型合成角膜装置在兔模型中的 12 个月临床和组织病理学性能。
Transl Vis Sci Technol. 2023 Aug 1;12(8):9. doi: 10.1167/tvst.12.8.9.
2
Metalloproteinase-9 in the ocular surface of patients with implanted Boston type 1 keratoprosthesis.植入波士顿1型人工角膜患者眼表中的金属蛋白酶-9
Cornea Open. 2023 Mar;2(1). doi: 10.1097/coa.0000000000000008. Epub 2023 Mar 27.
3
[Treatment of vascularized high-risk eyes with a Boston keratoprosthesis].
[用波士顿人工角膜治疗血管化高危眼]
Ophthalmologe. 2021 Jun;118(6):544-552. doi: 10.1007/s00347-021-01356-x. Epub 2021 Mar 17.
4
Outcomes of Boston keratoprosthesis type 1 reimplantation: multicentre study results.Boston 角膜型 1 再植入的结果:多中心研究结果。
Can J Ophthalmol. 2018 Jun;53(3):284-290. doi: 10.1016/j.jcjo.2017.10.021. Epub 2017 Dec 11.